Pharmadrug, Inc.

As of June 30, 2026, Pharmadrug, Inc. carries a market capitalization of 671,071.90, placing it among publicly traded companies globally. Its enterprise value stands at 2.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Pharmadrug, Inc. has 134.21M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Pharmadrug, Inc. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -99.81, indicating conservative leverage, while an interest coverage ratio of -0.44 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -96.36, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Pharmadrug, Inc.'s stock has declined approximately 50.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2026, Pharmadrug, Inc. generated - - in revenue and converted that into -641,108.00 in net income, yielding earnings per share of -0.01. EBITDA reached -174,031.00, while operating income came in at -224,275.00.

As of June 30, 2026, Pharmadrug, Inc. holds 23,060.00 in cash and equivalents against 1.71M in total debt, resulting in a net debt position of 1.68M. Total book value stands at -1.80M, with working capital of -2.12M providing operational flexibility.

Pharmadrug, Inc. produced -89,557.00 in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.78: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.14, meaning Pharmadrug, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Pharmadrug, Inc.'s most recent stock split took place on October 24, 2023 with a 7:1 split ratio.

As of June 30, 2026, Pharmadrug, Inc. has an Altman Z-Score of -224.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.